Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 6, 2016New England Journal of MedicineOpen Access

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

TMTony MokYWYi‐Long WuMAMyung‐Ju Ahn

Discussion

Loading...

Member takes

Overview

Randomized trial demonstrates superior efficacy of osimertinib over platinum-pemetrexed in EGFR T790M-positive advanced lung cancer, highlighting an effective targeted treatment after initial therapy.

Key Points

  • To assess the efficacy of osimertinib compared with platinum-based therapy plus pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer whose disease progressed during first-line EGFR-TKI therapy.
  • Interventional randomized trial (AURA3; ClinicalTrials.gov number, NCT02151981) in patients with EGFR T790M-positive advanced non-small-cell lung cancer.
  • Patients with progression on prior first-line EGFR-TKI therapy, including individuals with central nervous system metastases, received either osimertinib or platinum therapy plus pemetrexed.
  • Osimertinib produced significantly greater clinical efficacy compared to platinum therapy plus pemetrexed.
  • Superior treatment efficacy with osimertinib was also observed in the subgroup of patients with central nervous system metastases.

Cite This Study

Mok et al. (2016) studied this question.

synapsesocial.com/papers/69d9276fe0d31bb747836007https://doi.org/10.1056/nejmoa1612674
View Full Paper
Ask AI
Bookmark
Share